The Historic Move: Schedule I to Schedule III
On April 23, 2026, the U.S. Department of Justice and the DEA issued a final order that immediately moved specific categories of cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026.
This reclassification is limited in scope and applies only to:
- FDA-approved drug products containing marijuana
- Marijuana products subject to a qualifying state-issued medical marijuana license
What This Means for Medical Operators
For state-licensed medical marijuana entities, the order established a new, expedited federal registration pathway with the DEA. Operators who submit registration applications within 60 days may continue to operate under their state licenses while their federal applications are pending.
The most significant financial impact: the elimination of IRS Section 280E for qualifying entities. This provision previously prevented cannabis businesses from deducting standard business expenses, creating effective tax rates of 70-80%. Its removal could immediately improve cash flow and profitability.
What It Does NOT Cover
- This order does not legalize cannabis for recreational/adult use.
- It does not apply to hemp-derived products or other forms of cannabis not covered by a state medical license.
- Products outside the two specified categories remain Schedule I substances.
The Next Phase: Expedited Hearing
The DOJ has initiated a new administrative hearing process to evaluate the broader rescheduling of marijuana—including recreational use—from Schedule I to Schedule III. The hearing is scheduled to begin on June 29, 2026, and is expected to conclude by July 15, 2026.
Legal Challenges
The April rescheduling order faces legal scrutiny, with petitions filed in early May 2026 challenging the DOJ's authority and the process used to implement the change. The outcome of these challenges could affect the timeline and scope of further reform.